Date: 2016-03-17
Type of information: Resignation
Compound:
Company: GSK (UK)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On March 17, 2016, GSK announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017. The Board has agreed that he will retire on 31st March 2017. The Board will now conduct a formal search for a successor and will consider internal and external candidates for the role.
Financial terms:
Latest news:
